TY - JOUR
T1 - IL-12 gene therapy for cancer
T2 - In synergy with other immunotherapies
AU - Melero, Ignacio
AU - Mazzolini, Guillermo
AU - Narvaiza, Iñigo
AU - Qian, Cheng
AU - Chen, Lieping
AU - Prieto, Jesús
PY - 2001
Y1 - 2001
N2 - In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.
AB - In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.
UR - http://www.scopus.com/inward/record.url?scp=0034918717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034918717&partnerID=8YFLogxK
U2 - 10.1016/S1471-4906(00)01824-X
DO - 10.1016/S1471-4906(00)01824-X
M3 - Article
C2 - 11286714
AN - SCOPUS:0034918717
SN - 1471-4906
VL - 22
SP - 113
EP - 115
JO - Trends in Immunology
JF - Trends in Immunology
IS - 3
ER -